Alterations of Thyroid Function and Nutritional Status in Patients with Type 2 Diabetes Mellitus Complicated by Metabolic Syndrome Treated with Insulin Combined with Either Liraglutide or Dapagliflozin

Abstract

The present study compared the effectiveness of insulin plus liraglutide or dapagliflozin in treating type 2 diabetes mellitus complicated with metabolic syndrome and observed the nutritional status of patients before and after treatment. The results revealed no significant difference in the overall clinical efficacy and blood glucose levels between the liraglutide group treated with liraglutide and the dapagliflozin group treated with dapagliflozin (P > 0.05). In contrast, the adverse reactions in the liraglutide group were even lower than those in the control group (P < 0.05). In addition, the liraglutide group demonstrated better improvements in insulin metabolism and blood lipid levels than the dapagliflozin group after treatment. However, their ability to repair thyroid function and alleviate oxidative stress was comparatively weak (P < 0.05). Serum albumin, total protein, and transferrin levels were elevated in both groups after treatment, but the increase in the dapagliflozin group was higher than that in the liraglutide group (P < 0.05). The number of malnutrition cases was significantly reduced in both groups after treatment compared to before treatment (P < 0.05). These results suggest that the combination of insulin with liraglutide or dapagliflozin is highly effective in treating type 2 diabetes mellitus complicated by metabolic syndrome and can effectively improve the nutritional status of patients.